TTRV142I

There are 2 papers on TTRV142I in aging research: 2 observational studies in people. The newest story, Nov 9, 2026: “Genetic differences linked to heart failure risk in carriers”.

Gene

2 papers study it7 findings

1 new paper in 30 daysSee all 2 papers on TTRV142I

At a glance

The findings reach people, from one lab or study. 2 independent labs in 1 country.

“V142I carriers had significantly higher risks for HF or CM (HR: 1.20; 95% CI: 1.10-1.31)”
Systemic Manifestations and Mortality Risk in Transthyretin V142I Variant Carriers: A Million Veteran Program AnalysisJACC. CardioOncology2026doi:10.1016/j.jaccao.2025.12.006

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 2 independent labs in 1 country
  • Funders: Alnylam Pharmaceuticals and 8 more
  • 6 of 7 findings with company ties
  • Humans2

Associations

7

Incident heart failure hospitalization

upin humans1OR 1.8

1 study
  1. TTRV142I is associated with incident heart failure hospitalization in humans (individuals of African ancestry; V142I carriers versus non-carriers) (12.2% versus 7.2%; OR 1.80, 95% CI 1.18–2.74).

    “During follow-up, 12.2% of carriers and 7.2% of non-carriers experienced a HFH (Odds Ratio [OR] = 1.80; 95% Confidence Interval [CI]: 1.18-2.74).”

    Humansindividuals of African ancestry; V142I carriers versus non-carriers69.5% womens

    Genetic differences linked to heart failure risk in carriers

    AHA Scientific Sessions 2026 abstract

Mortality

upin humans1HR 1.12

1 study
  1. TTRV142I is associated with mortality in humans (African ancestry; V142I carriers compared with matched control subjects) (HR 1.12, 95% CI 1.01–1.25).

    “V142I carriers also had a significantly higher risk for all-cause mortality (HR: 1.12; 95% CI: 1.01-1.25)”

    HumansAfrican ancestry; V142I carriers compared with matched control subjects

    Systemic Manifestations and Mortality Risk in Transthyretin V142I Variant Carriers: A Million Veteran Program Analysis

    JACC. CardioOncology

Neuropathy

upin humans1HR 1.24

1 study
  1. TTRV142I is associated with neuropathy in humans (HR 1.24, 95% CI 1.13–1.36).

    “neuropathy (HR: 1.24; 95% CI: 1.13-1.36) compared with control subjects.”

    HumansAfrican ancestry; V142I carriers compared with matched control subjects, after multivariable adjustment

    Systemic Manifestations and Mortality Risk in Transthyretin V142I Variant Carriers: A Million Veteran Program Analysis

    JACC. CardioOncology

More on Neuropathy

Spinal stenosis

upin humans1HR 1.17

1 study
  1. TTRV142I is associated with spinal stenosis in humans (HR 1.17, 95% CI 1.07–1.28).

    “SS (HR: 1.17; 95% CI: 1.07-1.28)”

    HumansAfrican ancestry; V142I carriers compared with matched control subjects, after multivariable adjustment

    Systemic Manifestations and Mortality Risk in Transthyretin V142I Variant Carriers: A Million Veteran Program Analysis

    JACC. CardioOncology

More on Spinal stenosis

Carpal tunnel syndrome

upin humans1HR 1.43

1 study
  1. TTRV142I is associated with carpal tunnel syndrome in humans (HR 1.43, 95% CI 1.30–1.57).

    “CTS (HR: 1.43; 95% CI: 1.30-1.57)”

    HumansAfrican ancestry; V142I carriers compared with matched control subjects, after multivariable adjustment

    Systemic Manifestations and Mortality Risk in Transthyretin V142I Variant Carriers: A Million Veteran Program Analysis

    JACC. CardioOncology

More on Carpal tunnel syndrome

Atrial fibrillation/flutter

upin humans1HR 1.26

1 study
  1. TTRV142I is associated with atrial fibrillation/flutter in humans (HR 1.26, 95% CI 1.13–1.40).

    “V142I carriers had significantly higher risks for HF or CM (HR: 1.20; 95% CI: 1.10-1.31), AF or AFL (HR: 1.26; 95% CI: 1.13-1.40)”

    HumansAfrican ancestry; V142I carriers compared with matched control subjects, after multivariable adjustment

    Systemic Manifestations and Mortality Risk in Transthyretin V142I Variant Carriers: A Million Veteran Program Analysis

    JACC. CardioOncology

More on Atrial fibrillation/flutter

Heart failure or cardiomyopathy

upin humans1HR 1.2

1 study
  1. TTRV142I is associated with heart failure or cardiomyopathy in humans (HR 1.20, 95% CI 1.10–1.31).

    “V142I carriers had significantly higher risks for HF or CM (HR: 1.20; 95% CI: 1.10-1.31)”

    HumansAfrican ancestry; V142I carriers compared with matched control subjects, after multivariable adjustment

    Systemic Manifestations and Mortality Risk in Transthyretin V142I Variant Carriers: A Million Veteran Program Analysis

    JACC. CardioOncology

More on Heart failure or cardiomyopathy

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 12 papers in 12 months
AHA Scientific Sessions 2026 Abstract

Genetic differences linked to heart failure risk in carriers

One gene variant was linked to 7.34 times the odds of heart failure hospitalization in carriers of a heart-risk variant, compared with its absence.One gene variant was linked to 7.34 times the odds of heart failure hospitalization in carriers of a heart-risk variant, compared with its absence.

Genetic association studyHeart failure